Q3 Earnings Estimate for TNGX Issued By Leerink Partnrs

Tango Therapeutics, Inc. (NASDAQ:TNGX) – Research analysts at Leerink Partnrs issued their Q3 2025 earnings per share estimates for Tango Therapeutics in a report issued on Wednesday, February 5th. Leerink Partnrs analyst A. Berens anticipates that the company will post earnings per share of ($0.30) for the quarter. The consensus estimate for Tango Therapeutics’ current full-year earnings is ($1.19) per share. Leerink Partnrs also issued estimates for Tango Therapeutics’ FY2025 earnings at ($1.28) EPS, FY2026 earnings at ($1.36) EPS and FY2027 earnings at ($1.93) EPS.

Other analysts have also issued reports about the stock. B. Riley cut their target price on shares of Tango Therapeutics from $16.00 to $8.00 and set a “buy” rating for the company in a research note on Monday, November 11th. Guggenheim dropped their price target on Tango Therapeutics from $18.00 to $8.00 and set a “buy” rating on the stock in a report on Thursday, November 7th. Cantor Fitzgerald reissued an “overweight” rating on shares of Tango Therapeutics in a research note on Thursday, December 5th. Finally, HC Wainwright reaffirmed a “buy” rating and set a $13.00 target price on shares of Tango Therapeutics in a research report on Friday, November 8th. Eight investment analysts have rated the stock with a buy rating, Based on data from MarketBeat.com, the company presently has an average rating of “Buy” and a consensus target price of $13.14.

Tango Therapeutics Trading Down 8.8 %

Shares of Tango Therapeutics stock opened at $2.49 on Monday. Tango Therapeutics has a 52 week low of $2.46 and a 52 week high of $12.80. The stock has a market cap of $267.48 million, a PE ratio of -2.11 and a beta of 0.80. The company’s 50-day moving average price is $3.08 and its two-hundred day moving average price is $5.95.

Hedge Funds Weigh In On Tango Therapeutics

A number of institutional investors have recently made changes to their positions in TNGX. The Manufacturers Life Insurance Company increased its position in shares of Tango Therapeutics by 8.1% during the second quarter. The Manufacturers Life Insurance Company now owns 29,511 shares of the company’s stock valued at $253,000 after purchasing an additional 2,218 shares during the period. Teacher Retirement System of Texas boosted its stake in Tango Therapeutics by 35.8% during the fourth quarter. Teacher Retirement System of Texas now owns 14,544 shares of the company’s stock worth $45,000 after buying an additional 3,831 shares in the last quarter. China Universal Asset Management Co. Ltd. lifted its holdings in shares of Tango Therapeutics by 64.2% during the 3rd quarter. China Universal Asset Management Co. Ltd. now owns 20,607 shares of the company’s stock worth $159,000 after acquiring an additional 8,055 shares during the period. Quest Partners LLC boosted its position in shares of Tango Therapeutics by 1,448.4% during the 3rd quarter. Quest Partners LLC now owns 10,885 shares of the company’s stock valued at $84,000 after acquiring an additional 10,182 shares in the last quarter. Finally, Swiss National Bank raised its position in Tango Therapeutics by 13.1% in the fourth quarter. Swiss National Bank now owns 94,900 shares of the company’s stock worth $293,000 after purchasing an additional 11,000 shares in the last quarter. 78.99% of the stock is currently owned by institutional investors.

Insiders Place Their Bets

In other news, CEO Barbara Weber sold 9,778 shares of the firm’s stock in a transaction on Tuesday, February 4th. The shares were sold at an average price of $2.99, for a total transaction of $29,236.22. Following the transaction, the chief executive officer now owns 1,631,264 shares in the company, valued at approximately $4,877,479.36. This trade represents a 0.60 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, Director Mace Rothenberg purchased 10,000 shares of the firm’s stock in a transaction dated Monday, November 18th. The shares were bought at an average price of $3.78 per share, with a total value of $37,800.00. Following the purchase, the director now owns 31,250 shares in the company, valued at $118,125. This represents a 47.06 % increase in their position. The disclosure for this purchase can be found here. Insiders sold a total of 24,268 shares of company stock worth $72,561 in the last quarter. 6.30% of the stock is currently owned by corporate insiders.

About Tango Therapeutics

Tango Therapeutics, Inc, a biotechnology company, discovers and develops drugs for the treatment of cancer. Its lead program is TNG908, a synthetic lethal small molecule inhibitor of protein arginine methyltransferase 5 that is being developed as a treatment for cancers with methylthioadenosine phosphorylase deletions.